Thoraxklinik Heidelberg GmbH, Germany.
Lung Cancer. 2010 Aug;69 Suppl 1:S18-23. doi: 10.1016/S0169-5002(10)70134-3.
The new targeted agent bevacizumab in combination with cisplatin and gemcitabine, and a third-generation chemotherapy pemetrexed in combination with cisplatin, have been approved as first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSCLC). An indirect comparison between bevacizumab plus cisplatin and gemcitabine and pemetrexed plus cisplatin showed that bevacizumab (plus cisplatin and gemcitabine) achieved a favourable hazard ratio in terms of progression-free survival among patients with advanced NSCLC. This analysis aimed to compare the monthly cost of these treatments for advanced non-squamous NSCLC in Italy and Germany. The comparison used country specific cost data and adopted the payer perspective in Italy and Germany. The monthly cost of bevacizumab, including administration cost, as a single agent was 1,509 euro and 2,564 euro less than pemetrexed in Italy and Germany, respectively. The monthly treatment cost of bevacizumab plus cisplatin and gemcitabine was 1,001 euro and 446 euro less than pemetrexed plus gemcitabine in Italy and Germany, respectively. Results indicate that clinical benefits with bevacizumab plus cisplatin and gemcitabine therapy are achieved at a lower monthly cost than pemetrexed plus gemcitabine doublet therapy. Therefore, from a budget perspective, bevacizumab should be considered as a preferred targeted treatment of choice for advanced non-squamous NSCLC.
贝伐珠单抗联合顺铂和吉西他滨，以及第三代化疗培美曲塞联合顺铂，已被批准作为晚期非鳞状非小细胞肺癌（NSCLC）患者的一线治疗药物。贝伐珠单抗联合顺铂和吉西他滨与培美曲塞联合顺铂的间接比较表明，贝伐珠单抗（联合顺铂和吉西他滨）在晚期 NSCLC 患者的无进展生存期方面具有有利的风险比。本分析旨在比较意大利和德国晚期非鳞状 NSCLC 患者使用这些治疗方法的每月成本。该比较使用了特定国家的成本数据，并在意大利和德国采用了支付者的角度。在意大利和德国，贝伐珠单抗（包括管理费用）作为单一药物的每月费用比培美曲塞分别低 1509 欧元和 2564 欧元。贝伐珠单抗联合顺铂和吉西他滨的每月治疗费用比培美曲塞联合吉西他滨分别低 1001 欧元和 446 欧元。结果表明，与培美曲塞联合吉西他滨治疗相比，贝伐珠单抗联合顺铂和吉西他滨治疗的临床获益具有更低的每月成本。因此，从预算角度来看，贝伐珠单抗应被视为晚期非鳞状 NSCLC 的首选靶向治疗药物。
